AudiologyOnline Phone: 800-753-2160


Oticon Medical - BAHS - January 2024

Certain OTC, Less Expensive Hearing Aids Provide Benefit Similar to Conventional Hearing Aid

Share:

A comparison between less-expensive, over-the-counter hearing assistance devices and a conventional hearing aid found that some of these devices were associated with improvements in hearing similar to the hearing aid, according to a study published by JAMA.

Presently, hearing aids can only be purchased in the United States through a licensed professional, with an average cost of $4,700 for two hearing aids (uncovered by Medicare).  According to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use. Personal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.

Nicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss. The researchers found that the change in accuracy in speech understanding from unaided to aided varied by device. Three of the PSAPs were associated with improvements in speech understanding that were similar to results obtained with the hearing aid; one demonstrated little improvement; and speech understanding was worse with one PSAP.

“Results lend support to current national initiatives from the National Academies, White House, and bipartisan legislation requesting that the U.S. Food and Drug Administration create a new regulatory classification for hearing devices meeting appropriate specifications to be available over the counter,” the authors write.

A limitation of the study was the modest number of participants.

(doi:10.1001/jama.2017.6905)

Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Rexton Reach - November 2024

Our site uses cookies to improve your experience. By using our site, you agree to our Privacy Policy.